Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.37 |
| ▸ | GSR | P00390 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7289744 | 0.80 | KEAP1 (0.36) | KEAP1NFE2L2 | |
| SCHEMBL7289748 | 0.78 | CA2 (0.44) | KEAP1NFE2L2CA2 | |
| SCHEMBL10727966 | 0.78 | COMT (0.43) | KDM4ETHRB | |
| SCHEMBL3413877 | 0.78 | KEAP1 (0.60) | KDM4EHPGDKEAP1NFE2L2CYP1A2 | |
| SCHEMBL29291621 | 0.77 | KEAP1 (0.58) | KDM4EHPGDTXNRD1GSRKEAP1 | |
| SCHEMBL18958933 | 0.77 | KEAP1 (0.58) | KDM4EHPGDTXNRD1GSRKEAP1 | |
| SCHEMBL11788309 | 0.74 | SOAT1 (0.35) | FAAHTXNRD1GSRSOAT1 | |
| SCHEMBL11882105 | 0.74 | CA12 (0.36) | KDM4EHPGDFAAHTXNRD1GSR | |
| SCHEMBL22894765 | 0.73 | ALDH1A1 (0.37) | KDM4EKEAP1NFE2L2 | |
| SCHEMBL8910376 | 0.72 | HPGD (0.54) | KDM4EHPGDTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004108722-A1 | ORTHOCONDENSED POLYCYCLIC AMINOPYRROLE DERIVATIVES COMPRISING AN ELECTRO-ATTRACTIVE SUBSTITUENT, COMBINATION PRODUCTS OF SAID DERIVATIVES, AND METHOD FOR THE PRODUCTION THEREOF | PIERRE FABRE UROLOGIE (FR) | 2004-12-16 | — | — | WO | claimed |
| US-7112585-B2 | Pyrimidine derivatives as corticotropin releasing factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| WO-2004108722-A1 | ORTHOCONDENSED POLYCYCLIC AMINOPYRROLE DERIVATIVES COMPRISING AN ELECTRO-ATTRACTIVE SUBSTITUENT, COMBINATION PRODUCTS OF SAID DERIVATIVES, AND METHOD FOR THE PRODUCTION THEREOF | PIERRE FABRE UROLOGIE (FR) | 2004-12-16 | — | — | WO | disclosed |
| US-20040229891-A1 | Pyrimidine derivatives as corticotropin releasing factor inhibitors | HARTZ RICHARD A (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229891-A1 | Pyrimidine derivatives as corticotropin releasing factor inhibitors | CRH, CRHR1, CRHR2 | KDM4E 4445/4885HPGD 376/4885FAAH 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.